-

Zoetis Appoints Gavin D.K. Hattersley to its Board of Directors

Molson Coors’ President and Chief Executive Officer brings valuable business leadership and global public company experience to Zoetis Board

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Gavin D.K. Hattersley, President, Chief Executive Officer and Director of Molson Coors Beverage Company, to its Board of Directors.

Mr. Hattersley brings global public company leadership and board experience, including as a current Chief Executive Officer and former Chief Financial Officer of Molson Coors, to the Zoetis Board. He will serve on the Board’s Corporate Governance and Sustainability Committee.

“Gavin Hattersley brings invaluable experience to our Board as we continue to expand in key markets around the globe,” said Kristin Peck, Chief Executive Officer of Zoetis. “His experience as CEO of a public company will help Zoetis as we continue to advance our vision to be the most trusted and valued animal health company, shaping the future of animal care through our innovation, customer obsession and purpose-driven colleagues.”

“We are pleased to welcome Gavin to Zoetis’ Board of Directors, and we look forward to the contributions he will make as we continue to advance Zoetis as the leader in animal health and deliver innovation for our customers and the animals in their care,” said Zoetis Board Chair Michael McCallister.

Mr. Hattersley has served as Molson Coors’ CEO since September 2019. Prior to his current position, Mr. Hattersley held various positions within the company including Chief Executive Officer of MillerCoors, the former U.S. division of Molson Coors, and as Chief Financial Officer of Molson Coors’ global business. Prior to joining the company, he held several financial management positions with international businesses in the brewing and manufacturing sectors, including SAB Limited and Barloworld Limited. Mr. Hattersley holds an honors degree in accounting science and a bachelor’s degree from the University of South Africa. As a member of Molson Coors’ Board of Directors since 2019, Mr. Hattersley is poised to bring wide-ranging expertise to the Zoetis Board, from corporate development and P&L management to broad-based financial acumen.

“I am incredibly grateful for the opportunity to join Zoetis’ Board of Directors at an exciting time for the company,” Hattersley said. “Zoetis’ mission to lead the industry with best-in-class animal care solutions, a diversified portfolio and a winning company culture matches perfectly with my professional experience and personal values, and I look forward to playing a role in Zoetis’ bright future.”

With Mr. Hattersley’s appointment, Zoetis increased the size of the Board from 12 to 13 members.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

ZTS-COR

ZTS-IR

Contacts

Media:
Jenielle Alonso
1-973-945-4333 (o)
jenielle.alonso@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investors:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Versions
$Cashtags

Contacts

Media:
Jenielle Alonso
1-973-945-4333 (o)
jenielle.alonso@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investors:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation. In a nine-month field trial in Europe, Portela demonstrated effectiveness in alleviating OA pain and was found to be well...

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health. “The pace of animal health innovation is accelerating alongside a growing appreciation for the essential role animals play in our lives and communities....

Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve growth factor (NGF), recognized as an important mediator of pain and inflammation. Lenivia is built on a decade of s...
Back to Newsroom